THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH THE COMPANY'S UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS, THE NOTES THERETO AND THE OTHER FINANCIAL INFORMATION APPEARING IN THIS REPORT.





Introduction


The financial data discussed below are derived from the unaudited consolidated financial statements of the Company as of September 30, 2022, which were prepared and presented in accordance with United States generally accepted accounting principles for interim financial statements. These financial data are only a summary and should be read in conjunction with the unaudited financial statements and related notes contained herein, which more fully present the Company's financial condition and operations as at that date, and with its audited financial statements and notes thereto contained in its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on April 18, 2022. Further, the Company urges caution regarding the forward-looking statements which are contained in this report because they involve risks, uncertainties and other factors affecting its operations, market growth, service, products and licenses that may cause the Company's actual results and achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements. The occurrence of any of the events described in Part II, Item 1A, Risk Factors, or other events, could have a material adverse effect on the Company's business, results of operations and financial position.





General Statement of Business


The Company was incorporated under the laws of the state of Florida on September 5, 1997, under the corporate name Synthetic Flowers of America, Inc. It changed its corporate name to Acology, Inc. on January 9, 2014; on August 28, 2018, to Medtainer, Inc.; and on October 3, 2020, to its present name.

The Company is in the businesses of (i) selling and distributing hydroponic containers called "GrowPods" and related products and (ii) designing, branding and selling proprietary plastic medical-grade containers that can store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs, as well as selling other products such as humidity control inserts, smell-proof bags, lighters, and plastic lighter holders, and providing private labeling and branding for purchasers of the Company's containers and the other products.

The Company markets its products directly to businesses through its phone room and to the retail public through internet sales. The Company also markets directly to wholesalers and other businesses that resell them to other businesses and end users.

On October 9, 2020, the Company acquired all of the outstanding shares of Advanced Container Technologies, Inc., a California corporation ("Advanced"), from its shareholders pursuant to an Exchange Agreement, dated August 14, 2020, which was amended on September 9, 2020 (as so amended, the "Exchange Agreement"), in exchange for 50,000,000 shares of the Company's Common Stock. This exchange resulted in Advanced's becoming a wholly owned subsidiary of the Company.

The acquisition of ACT represented a material change in the business strategy of the Company and an expansion of its product base. Since the inception of the Company in 2014, its intended growth strategy was to concentrate on increasing sales of Medtainers while introducing related products and services, such as humidity control inserts and printing. This approach resulted in relatively flat revenues, increasing expenses and a history of losses. Management believes that this acquisition offered the prospect of substantially increased revenues, without a comparable increase in expenses an opportunity to expand its profits significantly. The Company has announced that it is exploring with GP the acquisition of its assets and the assumption of some or all of its liabilities in exchange for shares of Common Stock (the "GP Acquisition"). Discussions are in their preliminary stages and none of the terms and conditions of the acquisition has been determined, including the number of shares of Common Stock to be issued to GP in exchange for its assets or the liabilities of GP that the Company would assume. The Company intends to structure any transaction such that its board of directors and executive officers would not be changed and that voting control of the Company would not be affected.









  18





The Company's authorized capital is 100,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, par value $0.00001 per share. On October 3, 2020, the Company combined the outstanding shares of its Common Stock on the basis of one share for every 59 shares then outstanding; the number of authorized shares of Common Stock and preferred stock was unaffected. The effect of this combination has been applied to all periods covered by this report. The Company has also designated 1,000,000 shares of its preferred stock as Series A Convertible Preferred Stock ("Series A Preferred") and, on July 31, 2020, issued them to its chief executive officer in exchange for 305,085 shares of his Common Stock; these shares, together with the shares of Common Stock owned by him, confer voting control of the Company on him. See Item 10, Employment Agreement.

The Company's principal place of business is located at 1620 Commerce St., Corona, CA 92878. The Company's telephone number is (951) 381-2555. The Company has two corporate websites: www.advancedcontainertechnologies.com for GrowPods and related items and www.medtainer.com for Medtainers and related products and services. Common Stock is quoted on the OTC Pink tier of OTC Link, a quotation system operated by OTC Markets Group Inc. ("OTC Link"), under the trading symbol ACTX.





Going Concern



As indicated in Note 3 of the Notes to Consolidated Financial Statements, there is substantial doubt as to the ability of the Company to continue as a going concern. The Company has generated material operating losses since inception and its ability to continue as a going concern depends on the successful execution of its operating plan, which includes increasing sales of existing products - and in particular GrowPods and related products - while introducing additional products and services, controlling cost of goods sold and operation expenses, negotiating extensions of existing loans, and raising either debt or equity financing.





Need for Capital



The Company needs a substantial amount of additional capital to fund its business, including the expansion of its operations, and for repayment of its debts. No assurance can be given that any additional capital can be obtained or, if obtained, will be adequate to meet its needs. If adequate capital cannot be obtained on a timely basis and on satisfactory terms, the Company's operations could be materially negatively impacted and it may need to take certain measures to remain a going concern, or it could be forced to terminate operating.

Impact of the Covid-19 Pandemic

For more information regarding the impact of the Covid-19 pandemic on the Company, see Part II - Item 1A - Risk Factors.

Critical Accounting Policies and Estimates





Use of Estimates


The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Certain estimates could be affected by external conditions, including those unique to its industry and general economic conditions, which could affect the Company s estimates so as to cause actual results to differ materially from its estimates. The Company re-evaluates all of its accounting estimates at least quarterly, based on these conditions and records adjustments when necessary.

Significant estimates relied upon in preparing the consolidated financial statements contained in this report include revenue recognition, accounts receivable reserves, inventory and related reserves, valuations and purchase price allocations related to business combinations, expected future cash flows used to evaluate the recoverability of long-lived assets, estimated fair values of long-lived assets used to record impairment charges related to intangible assets and goodwill, amortization periods, accrued expenses, share-based compensation, and recoverability of the Company s net deferred tax assets and any related valuation allowances.









  19






Fair Value Measurements


The Company has adopted the provisions of ASC Topic 820, Fair Value Measurements, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair-value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, is carried on a historical cost basis, which approximates their fair value because of the short-term nature of these instruments. The carrying amounts of the Company s short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic 820 also establishes a fair-value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC Topic 820 describes three levels of inputs that may be used to measure fair value:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Goodwill and Intangible Asset Impairment

Goodwill and intangible assets that have indefinite useful lives are not amortized, but are evaluated for impairment annually or whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company records intangible assets at fair value when they are acquired and they are tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test consists of a comparison of the fair value of the indefinite-lived intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss will be recorded in the consolidated statements of operation in an amount equal to that excess. The Company amortizes its intangible assets that have finite lives using either the straight-line method or based upon estimated future cash flows to approximate the pattern in which the economic benefit of the assets will be utilized. Amortization is recorded over estimated useful lives ranging from 5 to 20 years.

Significant judgment is required in evaluating whether an intangible asset has an indefinite useful life and in testing for impairment. This judgment includes developing cash flow projections, selecting appropriate discount rates, identifying relevant market comparables, and incorporating general economic and market conditions.

The Company reviews intangible assets subject to amortization quarterly to determine if any adverse conditions exist or if a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that would indicate impairment and trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset or an adverse action or assessment by a regulator. If the carrying value of an intangible asset exceeds its undiscounted cash flows, the Company will write down its carrying value to its fair value in the period identified. The Company generally calculates fair value as the present value of estimated future cash flows to be generated by the asset using a risk-adjusted discount rate. If the estimate of an intangible asset's remaining useful life is changed, the Company will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life. The Company also evaluates intangible assets and long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. These changes include but are not limited to significant adverse changes in the business climate, market conditions, or other events, including the Covid-19 pandemic, that indicate an asset's carrying amount may not be recoverable. The recoverability of these assets is measured by comparing the carrying amount of each asset with the future undiscounted cash flows the asset is expected to generate. If the undiscounted cash flows used in the test of recoverability are less than the carrying amount of these assets, their carrying amount is reduced to fair value.









  20





Pursuant to ASU No. 2017-04, Simplifying the Test for Goodwill Impairment ("ASU No. 2017-04"), the Company evaluates and tests the recoverability of its goodwill for impairment at least annually during the fourth quarter of each fiscal year or more often if circumstances indicate that goodwill may not be recoverable. The Company has conducted annual impairment tests of goodwill during the fourth quarter of each year, commencing in the year ended December 31, 2018, in which year it first acquired intangible assets. The annual impairment testing process is subjective and requires judgment at many points. If these estimates or their related assumptions change, the Company may be required to record impairment charges for these assets. The Company operates as a single operating unit and consequently evaluates goodwill for impairment based upon an evaluation of the fair value of the Company as a whole. The estimation of fair value requires significant judgment. The goodwill recorded in the consolidated balance sheets at December 31, 2021, and December 31, 2020, was $1,020,314. Goodwill was due entirely to the Company s acquisition of intangible property relating to Medtainers in 2018. Various future events, including changes in demand for the Company s products and the Covid-19 pandemic, could result in an impairment of goodwill. Any adjustments resulting from an impairment test will be reflected in operating income in the Company s consolidated financial statements.

The fair value of acquired technology and patents, as well as acquired technology that the Company may develop, is determined at their acquisition date primarily using the income approach, which discounts expected future cash flows to present value. The discount rates used in the present value calculations are typically derived from a weighted-average cost-of-capital analysis and then adjusted to reflect risks inherent in the development life cycle as appropriate. Any loss resulting from an impairment test will be reflected in operating income in the Company s consolidated statements of income. The annual impairment testing process is subjective and requires judgment at many points. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges for these assets not previously recorded.

There was no impairment of intangible assets, long-lived assets or goodwill during the nine months ended September 30, 2022, and September 30, 2021.





Revenue Recognition


Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended by ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing; ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients; and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that it expects to receive for them.

Under ASU No. 2014-09, as amended, the Company recognizes revenues when a customer obtains control of promised goods or services, or when they are shipped to a customer, in an amount that reflects the consideration that it expects to receive in exchange for them. The Company recognizes revenues following a five-step model: (a) it identifies contract(s) with a customer; (b) it identifies the performance obligations in the contract; (c) it determines the transaction price; (d) it allocates the transaction price to the performance obligations in the contract; and (e) it recognizes revenues when (or as) it satisfies its performance obligation.

Revenues from product sales are recognized when a customer obtains control of the Company's product, which occurs at a point in time, typically upon shipment to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have been recognized is one year or less or the amount is immaterial.





Taxes


The Company accounts for income taxes under FASB ASC Topic 740, Accounting for Income Taxes, under which the Company is required to recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable.









  21






Results of Operations


Comparison of the Three Months Ended September 30, 2022, and September 30, 2021

The following table sets forth information from the statements of operations for the three months ended September 30, 2022, and September 30, 2021.





                                               Three Months Ended
                                  September 30, 2022       September 30, 2021
Revenues                          $           634,433     $          1,451,737
Cost of goods sold                           (486,892 )             (1,061,103 )
Gross profit                                  147,541                  390,634

Operating expenses                            546,759                  454,292
Loss from operations                         (399,218 )                (63,658 )

Non-operating income (expense):
Non-operating income                                -                  138,567
Interest expense                               (2,887 )                 (8,297 )
Net income (loss)                 $          (402,105 )   $             66,612




Revenues


Revenues were $634,433 and $1,451,737 for the three months ended September 30, 2022, and September 30, 2021, respectively. The decrease was primarily due to a$552,000 decrease in revenues from sales of GrowPods and related products due the Company's difficulty in marketing and selling GrowPods, a $202,801 decrease in revenues from sales of Medtainers and a $19,545 decrease in revenues from shipping charges.





Cost of Goods Sold



Cost of goods sold for the three months ended September 30, 2022, and September 30, 2021, were $486,892 and $1,061,103, respectively. The decrease was primarily due to a $494,500 decrease in the cost of GrowPods and a $40,427 decrease in the cost of Medtainers. The gross margin decreased from 27% to 23% maily due to lower GrowPod sales.





Operating Expenses



The following table sets forth operating expenses for the three months ended September 30, 2022, and September 30, 2021:





                                             Three Months Ended
                                 September 30, 2022       September 30, 2021
Advertising and marketing       $             20,687     $             31,578
Bad debt                                      35,000                        -
Depreciation and amortization                 75,735                   69,232
Professional fees                             81,026                   20,520
Payroll                                      204,584                  230,313
General and administrative                   129,727                  102,649
Total operating expenses        $            546,759     $            454,292



Operating expenses were $546,759 and $454,292 for the three months ended September 30, 2022, and September 30, 2021, respectively. The increase in operating expense was due to a $60,506 increase in professional fees, a $35,000 in bad debt and a $27,078 increase in general and administrative which was partially offset by a reduction of $25,729 in payroll and a reduction of $10,891 in advertising and marketing.









  22






Loss from Operations


Loss from operations increased from a loss of $63,658 for the three months ended September 30, 2021, to a loss of $399,218 for the three months ended September 30, 2022, primarily due to a $243,093 decrease in gross profit and a $92,467 increase in operating expense.





Other Income (Expense)


For the three months ended September 30, 2022, and September 30, 2021, interest expense was $2,887 and $8,297, respectively. Interest expense decreased $5,410 as a result of a repayment of a note payable. The decrease in other income for the three months ended September 30, 2022, was due to the recognition of gain on debt forgiveness related to the full forgiveness of the Payroll Protection Program SBA loan and interest in the amount of $138,567.





Net Income (Loss)


The net loss for the three months ended September 30, 2022, was $402,105 ($75,735 of which was non-cash expense for depreciation and amortization), versus a net income of $66,612 ($69,232 of which was non-cash expense for depreciation and amortization), for the three months ended September 30, 2021. As described above, the principal reason for this difference was a $133,157 decrease in non-operating income, as well as a $243,093 decrease in gross profits.

Comparison of the Nine Months Ended September 30, 2022, and September 30, 2021

The following table sets forth information from the statements of operations for the nine months ended September 30, 2022, and September 30, 2021.





                                                                Nine Months Ended
                                                         September 30,     September 30,
                                                             2022              2021
Revenues                                                 $   2,299,923     $   4,083,267
Cost of goods sold                                          (1,626,992 )      (3,102,972 )
Gross profit                                                   672,931           980,295

Operating expenses                                           1,503,412         1,625,548
Loss from operations                                          (830,481 )        (645,253 )

Non-operating income (expense):
Non-operating income                                                 -           138,567
Interest expense                                               (13,025 )         (21,087 )
Total non-operating income (expense), net                      (13,025 )        (117,480 )

Net loss                                                 $    (843,506 )   $    (527,773 )




Revenues


Revenues were $2,299,923 and $4,083,267 for the nine months ended September 30, 2022, and September 30, 2021, respectively. The difference was primarily due to a$1,622,350 decrease in revenues from sales of GrowPods due the Company's difficulty in marketing and selling GrowPods, a $291,551 decrease in revenues from Medtainer sales and a $64,087 decrease in revenues from humidity pack sales, partially offset by a $215,695 increase in lighter sales and a $27,035 increase in printing sales.









  23






Cost of Goods Sold


Cost of goods sold for the nine months ended September 30, 2022, and September 30, 2021, were $1,626,922 and $3,102,972, respectively. This decrease was primarily due to a $1,502,380 decrease in the cost of GrowPods, a $48,898 decrease in cost of Medtainers and a $36,913 decrease in cost of humidity pack inserts. This decrease was partially offset by a $147,607 increase in cost of lighters. The gross margin increased from 24% to 29% mainly due to higher lighter sales.





Operating Expenses



Operating expenses for the nine months ended September 30, 2022, and September 30, 2021, consisted of the following:





                                              Nine Months Ended
                                 September 30, 2022       September 30, 2021
Advertising and marketing       $             98,678     $             64,009
Bad debt                                      40,750                        -
Depreciation and amortization                214,274                  209,056
Professional fees                            233,925                  148,641
Share-based compensation                           -                  270,000
Payroll                                      613,888                  694,375
General and administrative                   301,897                  239,467
Total operating expenses        $          1,503,412     $          1,625,548



Operating expenses were $1,503,412 and $1,625,548 for the nine months ended September 30, 2022, and September 30, 2021, respectively. The decrease in operating expenses was due to a $270,000 decrease in share-based compensation, a $40,750 increase in bad debt and a $80,487 decrease in payroll expenses. This decrease was partially offset by an $85,284 increase in professional fees, a $62,430 increase in general and administrative and a $34,669 increase in advertising and marketing.





Loss from Operations


Loss from operations increased from a loss of $645,253 for the nine months ended September 30, 2021, to $830,481 for the nine months ended September 30, 2022, primarily due to a $307,364 decrease in gross profit and a $185,228 increase in operating expense.





Other Income (Expense)



For the nine months ended September 30, 2022, and September 30, 2021, interest expense was $13,025 and $21,087, respectively. Interest expense decreased $8,062 as a result of a repayment of notes payable. The decrease in other income for the nine months ended September 30, 2021, was due to the recognition of gain on debt forgiveness related to the full forgiveness of the Payroll Protection Program SBA loan and interest in the amount of $138,567.





Net Loss


Net loss for the nine months ended September 30, 2021, was $527,773 ($270,000 of which was non-cash expense for share-based compensation and $209,056 of which was non-cash expense for depreciation), versus a net loss of $843,506 ($214,274 of which was non-cash expense for depreciation and amortization) for the nine months ended September 30, 2022. As more fully described above, the principal reason for this difference was a $307,364 decrease in gross profit and a $130,505 decrease in other non-operating income, which was partially offset by a $270,000 decrease in share-based compensation.









  24





Liquidity and Capital Resources

As of September 30, 2022, the Company had $297,166 in cash and accounts receivable of $169,250. As of September 30, 2022, and December 31, 2021, the Company had a working capital deficit of $1,586,331 and $1,073,722, respectively. As of September 30, 2022, the Company had no commitments for capital expenditures. As of September 30, 2022, the Company had inventory of approximately 133,000 Medtainer products, approximately 100,000 units of other products and two GrowPod units.

During the nine months ended September 30, 2022, the Company experienced negative cash flow from operations of $23,023 and added $260,822 of cash flows from financing activities. During the nine months ended September 30, 2021, the Company experienced negative cash flow from operations of $497,796 and $375,991 of cash flows from financing activities. Cash used in operating activities was primarily a result of the Company's net loss, partially offset by the non-cash item of amortization and the decrease in operating assets and liabilities.

The decrease in cash provided from financing activities was primarily a result of stockholder loans and proceeds from the issuance of common stock, which was partially offset by a repayment of debt.

On May 4, 2020, the Company made a note in favor of Customers Bank in the principal amount of $137,690 pursuant to the terms of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") (the "PPP Loan") and pursuant to all regulations and guidance promulgated or provided by the SBA and other Federal agencies that are now, or may become, applicable to the loan. On August 5, 2021, the Company was notified that the Paycheck Protection Note and the interest accrued thereon had been forgiven in full, subject to review by the SBA. The principal and interest forgiven was recorded as non-operating income in the consolidated statement of operations for the quarter ending September 30, 2021.

In 2020, the Company received $137,690 from the PPP Loan and $210,000 from the sale of 348,983 shares of Common Stock to two private investors, and in 2021, the Company received $615,000 from sales of 485,000 Common Stock to private investors. The proceeds from these transactions, which total $962,690, are insufficient to meet the Company's capital needs, inasmuch as it believes that it will require approximately $1,000,000 in additional funding for the next 12 months, including approximately $600,000 to repay loans and interest that are past due, assuming that the Company's operating loss remains at the same level and that it does not acquire the assets of GP, as it announced it may on February 28, 2022. If it does consummate this acquisition, the Company believes that it would require approximately $2,300,000 in additional funding for the next 12 months, owing to increased expenses associated with operating and integrating the acquired business. The Company is seeking extensions of its past-due loans, and if it is successful in doing so, the amount of such funding will be reduced, but assurance can be given as to the extent that it will be successful. The Company plans to fund its activities principally through the sale of debt or equity securities to private investors and, if attained, its profits. There is no assurance that such funding will be available on acceptable terms or available at all, or that the Company will attain profitability. If the Company cannot raise sufficient funds when required or on acceptable terms, it may have to reduce significantly or discontinue its operations. To the extent that funds are raised by issuing equity securities or securities that are convertible into the Company's equity securities, its stockholders may experience significant dilution.

The Company had no other material commitments for capital expenditures as of September 30, 2022, or as of the date of this report.

The Company intends to devote its manpower and capital resources to increasing revenues, while working to reduce the cost of goods sold and operating expenses. Doing so depends on the successful execution of its operating plan, which includes increasing sales of existing products, introducing additional products and services, controlling cost of goods sold and operation expenses, negotiating extensions of existing loans and raising either debt or equity financing.

Off-Balance-Sheet Arrangements

The Company has no off-balance-sheet arrangements.

Recent Accounting Pronouncements

Refer to Note 2 of the accompanying financial statements.









  25

© Edgar Online, source Glimpses